公开(公告)号：US20210169898A1

公开(公告)日：2021-06-10

申请号：US17094432

申请日：2020-11-10

Applicant: Virginia Commonwealth University ,  Durect Corporation

Inventor： Shunlin Ren ,  Leyuan Xu ,  Yanxia Ning ,  Jin Koung Kim ,  WeiQi Lin ,  Mee Jean Kim ,  Andrew R. Miksztal ,  Hongwei Wu ,  Min L. Lee ,  Wilma Tamraz

IPC: A61K31/565 ,  A61Q19/00 ,  A61K9/19 ,  A61P31/04 ,  A61K47/10 ,  A61K31/575 ,  A61K8/63 ,  A61P17/06 ,  A61K31/724 ,  A61K9/00 ,  A61P3/06 ,  A61K47/40 ,  A61K8/73 ,  A61P1/16 ,  C07J31/00

Abstract: Compositions comprising 5-cholesten-3, 25-diol, 3-sulfate (25HC3S) or pharmaceutically acceptable salt thereof and at least one cyclic oligosaccharide, e.g., a cyclodextrin (CD), are provided. The compositions may be used to prevent and/or treat a variety of diseases and conditions, including organ failure (e.g. acute liver failure), high cholesterol/high lipids, and various inflammatory diseases and conditions.

公开(公告)号：US20160264615A1

公开(公告)日：2016-09-15

申请号：US15042244

申请日：2016-02-12

Applicant: Virginia Commonwealth University

Inventor： Shunlin Ren ,  William M. Pandak

IPC: C07J31/00

CPC classification number: C07J31/006 ,  C07J9/00

Abstract: The sulfated oxysterol 5-cholesten-3β, 25-diol 3-sulphate, a nuclear cholesterol metabolite that decreases lipid biosynthesis and increases cholesterol secretion and degradation, is provided as an agent to lower intracellular and serum cholesterol and/or triglycerides, and to prevent or treat lipid accumulation-associated inflammation and conditions associated with such inflammation. Methods which involve the use of this sulfated oxysterol to treat conditions associated with high cholesterol and/or high triglycerides and/or inflammation (e.g. hypercholesterolemia, hypertriglyceridemia, non-alcoholic fatty liver diseases, atherosclerosis, etc.) are also provided.

Abstract translation: 提供了降低脂质生物合成并增加胆固醇分泌和降解的核胆固醇代谢产物硫酸氢化甾醇5胆甾醇-3β，25-二醇3-硫酸酯，作为降低细胞内和血清胆固醇和/或甘油三酯的药物，并防止 或治疗与这种炎症相关的脂质积聚相关的炎症和病症。 还提供涉及使用该硫酸化氧固醇来治疗与高胆固醇和/或高甘油三酸酯和/或炎症相关的病症（例如高胆固醇血症，高甘油三酯血症，非酒精性脂肪性肝病，动脉粥样硬化等）的方法。

公开(公告)号：US20230293551A1

公开(公告)日：2023-09-21

申请号：US18008582

申请日：2021-06-25

Applicant: Durect Corporation ,  Virginia Commonwealth University ,  The United States Government as Represented by the Department of Veterans Affairs

Inventor： Shunlin Ren ,  Yaping Wang ,  WeiQi Lin

IPC: A61K31/575 ,  A61P37/02

CPC classification number: A61K31/575 ,  A61P37/02

Abstract: Aspects of the present disclosure include methods for treating at least one autoimmune condition, such as at least one of hepatitis, multiple sclerosis, systemic lupus erythematosus, and rheumatoid arthritis. In some cases, the at least one autoimmune condition is associated with Epstein-Barr virus infection. In practicing the subject methods, an effective amount of at least one compound selected from 25-hydroxycholesterol-3-sulfate (25HC3S), 25-hydroxycholesterol-disulfate (25HCDS), 27-hydroxycholesterol-3-sulfate (27HC3S), 27-hydroxycholesterol-disulfate (27HCDS), 24-hydroxycholesterol-3-sulfate (24HC3S), 24-hydroxycholesterol-disulfate (24HCDS), and 24,25-epoxycholesterol-3-sulfate, or salt thereof is administered to the subject.

公开(公告)号：US11406646B2

公开(公告)日：2022-08-09

申请号：US17094432

申请日：2020-11-10

Applicant: Virginia Commonwealth University ,  Durect Corporation

Inventor： Shunlin Ren ,  Leyuan Xu ,  Yanxia Ning ,  Jin Koung Kim ,  WeiQi Lin ,  Andrew R. Miksztal ,  Hongwei Wu ,  Min L. Lee

IPC: A61K31/565 ,  A61P1/16 ,  A61K31/724 ,  A61K47/10 ,  A61K31/575 ,  A61K47/40 ,  A61P17/06 ,  A61P3/06 ,  A61P31/04 ,  A61Q19/00 ,  A61K8/73 ,  A61K9/19 ,  A61K9/00 ,  A61K8/63 ,  C07J31/00

Abstract: Compositions comprising 5-cholesten-3,25-diol, 3-sulfate (25HC3S) or pharmaceutically acceptable salt thereof and at least one cyclic oligosaccharide, e.g., a cyclodextrin (CD), are provided. The compositions may be used to prevent and/or treat a variety of diseases and conditions, including organ failure (e.g. acute liver failure), high cholesterol/high lipids, and various inflammatory diseases and conditions.

公开(公告)号：US20210238219A1

公开(公告)日：2021-08-05

申请号：US17122647

申请日：2020-12-15

Applicant: Virginia Commonwealth University

Inventor： Shunlin Ren

IPC: C07J31/00 ,  A61J1/14

Abstract: 5-cholesten, 3(3, 25-diol, disulfate (25HCDS) has been found to be an authentic PPARγ agonist and LXR antagonist, and is used for the therapy of lipid disorders and inflammatory diseases, including without limitation fatty liver, inflammatory bowel, and atherosclerotic disease.

公开(公告)号：US20200009158A1

公开(公告)日：2020-01-09

申请号：US16430895

申请日：2019-06-04

Applicant: Virginia Commonwealth University

Inventor： Shunlin Ren

IPC: A61K31/575 ,  A01K67/027 ,  C12N9/10

Abstract: Methods and compositions for the prevention and treatment of liver damage or disease in a subject in need thereof are provided. The methods involve providing the sulfated oxysterol 25-hydroxycholesterol-3-sulfate (25HC3S) to the subject e.g. by 1) administering 25HC3S to the subject; or 2) overexpressing, in the subject, the hydroxysterol sulfotransferase enzyme SULT2B1b, which catalyzes the sulfation of 25-hydroxycholesterol (25HC) to form 25HC3S.

公开(公告)号：US20190269695A1

公开(公告)日：2019-09-05

申请号：US16320079

申请日：2017-08-01

Applicant: Virginia Commonwealth University ,  Durect Corporation

Inventor： Shunlin Ren ,  Leyuan Xu ,  Yanxia Ning ,  Jin Koung Kim ,  WeiQi Lin ,  Mee Jean Kim ,  Andrew R. Miksztal ,  Hongwei Wu ,  Min L. Lee ,  Wilma Tamraz

IPC: A61K31/565 ,  A61P1/16 ,  A61P17/06 ,  A61P3/06 ,  A61P31/04 ,  A61K31/724 ,  A61K47/10

Abstract: Compositions comprising 5-cholesten-3, 25-diol, 3-sulfate (25HC3S) or pharmaceutically acceptable salt thereof and at least one cyclic oligosaccharide, e.g., a cyclodextrin (CD), are provided. The compositions may be used to prevent and/or treat a variety of diseases and conditions, including organ failure (e.g. acute liver failure), high cholesterol/high lipids, and various inflammatory diseases and conditions.

公开(公告)号：US20190169225A1

公开(公告)日：2019-06-06

申请号：US16154007

申请日：2018-10-08

Applicant: Virginia Commonwealth University

Inventor： Shunlin Ren ,  William M. Pandak

IPC: C07J31/00 ,  C07J9/00

Abstract: The sulfated oxysterol 5-cholesten-3β, 25-diol 3-sulphate, a nuclear cholesterol metabolite that decreases lipid biosynthesis and increases cholesterol secretion and degradation, is provided as an agent to lower intracellular and serum cholesterol and/or triglycerides, and to prevent or treat lipid accumulation-associated inflammation and conditions associated with such inflammation. Methods which involve the use of this sulfated oxysterol to treat conditions associated with high cholesterol and/or high triglycerides and/or inflammation (e.g. hypercholesterolemia, hypertriglyceridemia, non-alcoholic fatty liver diseases, atherosclerosis, etc.) are also provided.

公开(公告)号：US20190135856A1

公开(公告)日：2019-05-09

申请号：US16140964

申请日：2018-09-25

Applicant: VIRGINIA COMMONWEALTH UNIVERSITY

Inventor： Shunlin Ren

IPC: C07J31/00 ,  A61J1/14

Abstract: 5-cholesten, 3β, 25-diol, disulfate (25HCDS) has been found to be an authentic PPARγ agonist and LXR antagonist, and is used for the therapy of lipid disorders and inflammatory diseases, including without limitation fatty liver, inflammatory bowel, and atherosclerotic diseases.

公开(公告)号：US20230372361A1

公开(公告)日：2023-11-23

申请号：US18008605

申请日：2021-06-25

Applicant: Durect Corporation ,  Virginia Commonwealth University ,  The United States Government as Represented by the Department of Veterans Affairs

Inventor： Shunlin Ren ,  Yaping Wang ,  WeiQi Lin ,  James E. Brown ,  Felix Theeuwes

IPC: A61K31/575 ,  A61P29/00

CPC classification number: A61K31/575 ,  A61P29/00

Abstract: Aspects of the present disclosure include methods for treating at least one inflammatory condition, such as at least one of dental pulp inflammation, periodontal disease, skin inflammation, psoriasis, ulcerative colitis, osteoarthritis, inflammatory bowel disease (IBD), Crohn's disease, irritable bowel syndrome (IBS), Alzheimer's disease, Parkinson's disease, pancreatitis (acute and/or chronic), hepatitis (viral and/or non-viral), atherosclerosis, myocarditis, idiopathic pulmonary disorder (IPD), chronic obstructive pulmonary disorder (COPD), pneumonia, chronic inflammatory lung disease, bronchitis, asthma, chronic kidney disease (CKD), nephritis, sepsis, ankylosing spondylitis, diverticulitis, and fibromyalgia. In some cases, the at least one inflammatory condition is associated with Epstein-Ban virus infection. In practicing the subject methods, an effective amount of at least one compound selected from 25-hydroxycholesterol-3-sulfate (25HC3S), 25-hydroxycholesterol-disulfate (25HCDS), 27-hydroxycholesterol-3-sulfate (27HC3S), 27-hydroxycholesterol-disulfate (27HCDS), 24-hydroxycholesterol-3-sulfate (24HC3S), 24-hydroxycholesterol-disulfate (24HCDS), and 24,25-epoxycholesterol-3-sulfate, or salt thereof is administered to the subject.